Treatment with olanzapine, risperidone or typical antipsychotic drugs in Asian patients with schizophrenia

Objective: To examine clinical outcomes in Asian patients with schizophrenia receiving monotherapy with olanzapine, risperidone or typical antipsychotics in naturalistic settings. Method: In this report, data from the first 12 months of the prospective, observational, 3-year Intercontinental Schizop...

Full description

Bibliographic Details
Main Authors: Lee, C., Wu, K.H., Habil, H., Dyachkova, Y., Lee, P.
Format: Article
Language:English
Published: 2006
Subjects:
Online Access:http://eprints.um.edu.my/11049/1/Lee-2006-Treatment_with_olanz.pdf
_version_ 1825719955246546944
author Lee, C.
Wu, K.H.
Habil, H.
Dyachkova, Y.
Lee, P.
author_facet Lee, C.
Wu, K.H.
Habil, H.
Dyachkova, Y.
Lee, P.
author_sort Lee, C.
collection UM
description Objective: To examine clinical outcomes in Asian patients with schizophrenia receiving monotherapy with olanzapine, risperidone or typical antipsychotics in naturalistic settings. Method: In this report, data from the first 12 months of the prospective, observational, 3-year Intercontinental Schizophrenia Outpatient Health Outcomes study are presented for patients from participating Asian countries (Korea, Taiwan and Malaysia) who were started on, or switched to, monotherapy with olanzapine (n = 484), risperidone (n = 287) or a typical antipsychotic drug (n = 127) at baseline. Results: At 12 months, overall reduction in the score of Clinical Global Impressions-Severity of Illness rating scale was greatest with olanzapine (p < 0.001 vs typical agents), followed by risperidone (p = 0.007 vs typical agents) treatment. Olanzapine treatment was found to have significantly better effects than typical agents on negative and depressive symptom scores, and significantly greater improvements than risperidone on negative and cognitive symptoms. The occurrence of extrapyramidal symptoms was least likely with olanzapine (p < 0.001 vs typical agents, and p = 0.012 vs risperidone), while the estimated odds of tardive dyskinesia were greatest in the typical treatment group (p = 0.046 vs olanzapine, and p = 0.082 vs risperidone). Mean weight increase was greater for olanzapine-treated patients compared with the other agents (p = 0.030 vs typical agents and p < 0.001 vs risperidone). The risk of menstrual disturbance was relatively high with risperidone when compared with olanzapine treatment (p < 0.001). Conclusions: The results of this observational study indicate that, in Asian patients with schizophrenia, olanzapine may offer benefits when compared with typical agents or risperidone. However, the significantly greater odds of weight gain should be considered in the clinical management of olanzapine-treated patients.
first_indexed 2024-03-06T05:27:38Z
format Article
id um.eprints-11049
institution Universiti Malaya
language English
last_indexed 2024-03-06T05:27:38Z
publishDate 2006
record_format dspace
spelling um.eprints-110492014-10-13T01:25:31Z http://eprints.um.edu.my/11049/ Treatment with olanzapine, risperidone or typical antipsychotic drugs in Asian patients with schizophrenia Lee, C. Wu, K.H. Habil, H. Dyachkova, Y. Lee, P. R Medicine Objective: To examine clinical outcomes in Asian patients with schizophrenia receiving monotherapy with olanzapine, risperidone or typical antipsychotics in naturalistic settings. Method: In this report, data from the first 12 months of the prospective, observational, 3-year Intercontinental Schizophrenia Outpatient Health Outcomes study are presented for patients from participating Asian countries (Korea, Taiwan and Malaysia) who were started on, or switched to, monotherapy with olanzapine (n = 484), risperidone (n = 287) or a typical antipsychotic drug (n = 127) at baseline. Results: At 12 months, overall reduction in the score of Clinical Global Impressions-Severity of Illness rating scale was greatest with olanzapine (p < 0.001 vs typical agents), followed by risperidone (p = 0.007 vs typical agents) treatment. Olanzapine treatment was found to have significantly better effects than typical agents on negative and depressive symptom scores, and significantly greater improvements than risperidone on negative and cognitive symptoms. The occurrence of extrapyramidal symptoms was least likely with olanzapine (p < 0.001 vs typical agents, and p = 0.012 vs risperidone), while the estimated odds of tardive dyskinesia were greatest in the typical treatment group (p = 0.046 vs olanzapine, and p = 0.082 vs risperidone). Mean weight increase was greater for olanzapine-treated patients compared with the other agents (p = 0.030 vs typical agents and p < 0.001 vs risperidone). The risk of menstrual disturbance was relatively high with risperidone when compared with olanzapine treatment (p < 0.001). Conclusions: The results of this observational study indicate that, in Asian patients with schizophrenia, olanzapine may offer benefits when compared with typical agents or risperidone. However, the significantly greater odds of weight gain should be considered in the clinical management of olanzapine-treated patients. 2006 Article PeerReviewed application/pdf en http://eprints.um.edu.my/11049/1/Lee-2006-Treatment_with_olanz.pdf Lee, C. and Wu, K.H. and Habil, H. and Dyachkova, Y. and Lee, P. (2006) Treatment with olanzapine, risperidone or typical antipsychotic drugs in Asian patients with schizophrenia. Australian and New Zealand Journal of Psychiatry, 40 (5). pp. 437-445. ISSN 0004-8674, DOI https://doi.org/10.1080/j.1440-1614.2006.01820.x <https://doi.org/10.1080/j.1440-1614.2006.01820.x>. http://onlinelibrary.wiley.com/doi/10.1111/j.1440-1614.2006.01820.x/abstract?deniedAccessCustomisedMessage=&userIsAuthenticated=false 10.1080/j.1440-1614.2006.01820.x
spellingShingle R Medicine
Lee, C.
Wu, K.H.
Habil, H.
Dyachkova, Y.
Lee, P.
Treatment with olanzapine, risperidone or typical antipsychotic drugs in Asian patients with schizophrenia
title Treatment with olanzapine, risperidone or typical antipsychotic drugs in Asian patients with schizophrenia
title_full Treatment with olanzapine, risperidone or typical antipsychotic drugs in Asian patients with schizophrenia
title_fullStr Treatment with olanzapine, risperidone or typical antipsychotic drugs in Asian patients with schizophrenia
title_full_unstemmed Treatment with olanzapine, risperidone or typical antipsychotic drugs in Asian patients with schizophrenia
title_short Treatment with olanzapine, risperidone or typical antipsychotic drugs in Asian patients with schizophrenia
title_sort treatment with olanzapine risperidone or typical antipsychotic drugs in asian patients with schizophrenia
topic R Medicine
url http://eprints.um.edu.my/11049/1/Lee-2006-Treatment_with_olanz.pdf
work_keys_str_mv AT leec treatmentwitholanzapinerisperidoneortypicalantipsychoticdrugsinasianpatientswithschizophrenia
AT wukh treatmentwitholanzapinerisperidoneortypicalantipsychoticdrugsinasianpatientswithschizophrenia
AT habilh treatmentwitholanzapinerisperidoneortypicalantipsychoticdrugsinasianpatientswithschizophrenia
AT dyachkovay treatmentwitholanzapinerisperidoneortypicalantipsychoticdrugsinasianpatientswithschizophrenia
AT leep treatmentwitholanzapinerisperidoneortypicalantipsychoticdrugsinasianpatientswithschizophrenia